All In Biotech

Drug Trial Radar · NCT06669351

Study to Assess the Safety and Efficacy of ZX-7101A in Children Aged 5-11 Years With Influenza

A Multicenter, Randomized, Double-blind, Positive Controlled Phase Ⅲ Clinical Trial of ZX-7101A Tablets to Evaluate the Safety and Efficacy in the Treatment of Uncomplicated Influenza in Children Aged 5-11 Years

Last checked: Nov 20, 2026Latest source record: Aug 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

98

Actual

Start

Oct 31, 2024

Primary completion

Jul 15, 2025

Study completion Jul 15, 2025

Sponsor

Sponsor type
Industry
First posted
Nov 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 5 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter, randomized, double-blind, positive controlled, phase III trial to evaluate the safety and efficacy of ZX-7101A tablets versus oseltamivir phosphate suspension in children aged ≥5 years and \< 12 years with uncomplicated influenza.

Conditions

  • Respiratory Viral Infection

Interventions

  • ZX-7101ADrug

    On day1: Take two tablets of ZX-7101A orally once (specification: 10mg/ tablet) with appropriate amount of warm water

  • Placebo for ZX-7101A tabletOther

    Placebo for ZX-7101A tablet: The appearance and properties of placebo tablets were identical to those of the trial drug ZX-7101A tablets. On Day 1, two placebo for ZX-7101A tablets were taken orally with appropriate warm water.

  • Oseltamivir phosphate dry suspensionDrug

    Drug: Oseltamivir phosphate dry suspension: From Day1 to Day 5 : Oseltamivir phosphate suspension was orally administered twice a day, dose according to the label.

  • Placebo for Oseltamivir phosphate dry suspension:Other

    Drug: Placebo for Oseltamivir phosphate dry suspension: From Day1 to Day 5 : Placebo for Oseltamivir phosphate suspension was orally administered twice a day, dose according to the label.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetic parameters of ZX-7101A and its metabolite ZX-7101 in plasmaTime frame: Part 1: 1~2, 4, 8, 24, 96 ,192, 336 hours post-dose
  2. Pharmacokinetic parameters of ZX-7101A and its metabolite ZX-7101 in plasmaTime frame: Part 1: 1~2, 4, 8, 24, 96 ,192, 336 hours post-dose
  3. Pharmacokinetic parameters of ZX-7101A and its metabolite ZX-7101 in plasmaTime frame: Part 1: 1~2, 4, 8, 24, 96 ,192, 336 hours post-dose
  4. Pharmacokinetic parameters of ZX-7101A and its metabolite ZX-7101 in plasmaTime frame: Part 1: 1~2, 4, 8, 24, 96 ,192, 336 hours post-dose
  5. Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v5.0Time frame: Part 2: From day1 up to day15

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Baoding Hospital of Beijing Children's Hospital, Capital Medical University

    Baoding, Hebei, China

  • West China Second University Hospital, Sichuan University

    Chengdu, Sichuan, China

  • Children's Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.